Short leukocyte telomere length is associated with obesity in American Indians: The strong heart family study

Shufeng Chen1,2, Fawn Yeh3, Jue Lin4, Tet Matsuguchi4, Elizabeth Blackburn4, Elisa T. Lee3, Barbara V. Howard5, and Jinying Zhao1

1Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112, USA;
2Department of Evidence Based Medicine and Division of Population Genetics, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute and Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;
3Center for American Indian Health Research, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA;
4Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143, USA;
5MedStar Health Research Institute, Hyattsville, MD 20782, and Georgetown/Howard Universities Center for Clinical and Translational Science, Washington, DC 20007, USA.

Key words: obesity, Leukocyte telomere length, American Indians, strong heart family study

Received: 4/14/14; Accepted: 5/10/14; Published: 5/15/14

Correspondence to: Jinying Zhao, MD/PhD E-mail: jzhao5@tulane.edu

Copyright: © Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract Shorter leukocyte telomere length (LTL) has been associated with a wide range of age-related disorders including cardiovascular disease (CVD) and diabetes. Obesity is an important risk factor for CVD and diabetes. The association of LTL with obesity is not well understood. This study for the first time examines the association of LTL with obesity indices including body mass index, waist circumference, percent body fat, waist-to-hip ratio, and waist-to-height ratio in 3,256 American Indians (14-93 years old, 60% women) participating in the Strong Heart Family Study. Association of LTL with each adiposity index was examined using multivariate generalized linear mixed model, adjusting for chronological age, sex, study center, education, lifestyle (smoking, alcohol consumption, and total energy intake), high-sensitivity C-reactive protein, hypertension and diabetes. Results show that obese participants had significantly shorter LTL than non-obese individuals (age-adjusted P=0.0002). Multivariate analyses demonstrate that LTL was significantly and inversely associated with all of the studied obesity parameters. Our results may shed light on the potential role of biological aging in pathogenesis of obesity and its comorbidities.

INTRODUCTION

Telomeres are specialized nucleotide (TTAGGG)ₙ repeats and their associated proteins on the distal ends of human chromosomes. They are critical in maintaining chromosomal stability during mitotic cell proliferation. Because of the end-replication problem, telomere length shortens progressively during each round of cell division [1]. Telomere length declines gradually with age and has been used as a valuable biomarker for cellular senescence and biological aging. Shorter leukocyte telomere length (LTL) has been associated with a variety of age-related disorders, such as hypertension [2], diabetes [3], cardiovascular diseases (CVD) [4, 5] and certain types of cancers [6, 7].

Obesity is an escalating health problem that is associated with aging and age-related diseases. The prevalence of obesity is reaching epidemic proportions among all ethnic groups including American Indians.
Although the precise mechanisms linking obesity to age-related disorders remain largely unknown, it is possible that biological aging driven by telomere shortening plays a central role. In cross-sectional epidemiological studies, shorter LTL has been associated with body mass index (BMI), waist-to-hip ratio (WHR) and visceral fat [8, 9]. In an intervention trial of 521 subjects, reduction in adiposity indices corresponding to a Mediterranean diet intervention was accompanied by increased LTL [10], probably through telomere maintenance [11]. Weight loss induced by calorie-restricted diets was also associated with increased telomere length in rectal mucosa of obese men [12]. However, these findings were primarily derived from European Caucasians in relatively small subgroups of patients or research subjects, and results were inconsistent across study populations [13-17]. Given the potential impact of genetic [18-20] and lifestyle [21, 22] factors on telomeric aging and obesity pathologies, confirmation of previous findings in other ethnic groups with a wide range of age distribution in community-based populations is clearly required.

Obesity and overweight are highly prevalent among American Indians [23], a minority group that may have distinct genetic makeup and lifestyle factors in comparison with other populations [24]. Short LTL has been significantly predictive of type 2 diabetes [3] and carotid atherosclerosis (unpublished data) in this population. The purpose of this study is to examine the possible association of LTL with obesity in American Indians participating in the Strong Heart Family Study (SHFS).

RESULTS

Characteristics of the study participants

Among the 3,256 participants (1,941 women; mean age, 38.7 years), 1,871 (57.5%) participants were obese. The prevalence of obesity in AZ (73.7%) was significantly higher than that in OK (52.6%) and DK (46.1%). Women were more likely to be obese (60.6%) than men (52.8%). The prevalence of diabetes and hypertension was 20.6% and 31.3%, respectively. Compared with non-obese individuals, obese individuals were older, had shorter LTL, higher levels of blood pressure, fasting glucose, unfavorable lipid profiles, and higher prevalence of hypertension and diabetes, but obese participants were less likely to be current smokers or drinkers (Table S1).

| Table 1. Characteristics of study participants by LTL quintiles |
|---------------------------------------------------------------|
| **Variables** | **Quintile 1** | **Quintile 2** | **Quintile 3** | **Quintile 4** | **Quintile 5** | **P for trend** |
|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| N              | 651            | 651            | 652            | 651            | 651            |                |
| LTL (T/S ratio) | 0.68±0.11      | 0.88±0.04      | 0.99±0.03      | 1.09±0.04      | 1.31±0.16      | <0.0001*       |
| Age (years)    | 47.6±15.9      | 42.5±15.9      | 39.1±15.9      | 34.5±15.2      | 30.0±14.0      | <0.0001*       |
| Men, n (%)     | 271 (41.6)     | 267 (41.0)     | 270 (41.4)     | 241 (37.0)     | 266 (40.9)     | 0.009*         |
| Education (years) | 12.0±2.3   | 11.9±2.4      | 12.0±2.3      | 11.8±2.3      | 11.5±2.2      | 0.10*          |
| Energy intake (kcal) | 2586±1764 | 2530±1777 | 2661±1826 | 2996±2806 | 2727±1907 | 0.15*          |
| WC (cm)        | 107.8±17.7     | 106.4±18.6     | 104.9±18.5     | 103.6±17.7     | 98.0±17.6      | <0.0001*       |
| Percent body fat (%) | 37.7±10.0 | 38.0±9.9      | 37.3±9.9      | 37.9±10.4      | 35.4±10.8      | 0.57*          |
| BMI (kg/m²)    | 33.0±7.6       | 33.2±8.4       | 32.5±7.8       | 32.2±7.5       | 30.1±7.6       | <0.0001*       |
| WHR            | 0.93±0.08      | 0.91±0.08      | 0.91±0.08      | 0.90±0.08      | 0.89±0.08      | <0.0001*       |
| WHtR           | 0.65±0.11      | 0.64±0.11      | 0.63±0.11      | 0.62±0.11      | 0.58±0.11      | <0.0001*       |
| Fasting Glucose (mg/dL) | 124.8±62.7 | 119.0±55.2 | 113.3±52.3 | 108.6±50.3 | 101.0±34.6 | 0.001*         |
| hsCRP (mg/L)   | 7.94±9.73      | 7.43±9.62      | 6.30±7.52      | 6.06±7.50      | 5.04±7.01      | <0.0001*       |
| Physical activity (steps/d) | 5164±3852 | 5426±3684 | 5691±3553 | 6092±4187 | 6478±4012 | 0.40*          |
| Smoking, n (%) | 218 (33.8)     | 207 (31.8)     | 236 (36.3)     | 229 (35.2)     | 224 (34.4)     | 0.16*          |
| Drinking, n (%) | 345 (53.5)  | 373 (57.4)     | 378 (58.1)     | 403 (61.9)     | 426 (65.4)     | 0.18*          |
| Hypertension, n (%) | 265 (40.7) | 246 (37.8) | 204 (31.3) | 187 (28.8) | 116 (17.8) | 0.88*          |
| Diabetes, n (%) | 205 (31.5)     | 177 (27.3)     | 127 (19.5)     | 97 (14.9)      | 63 (9.7)       | <0.0001*       |
| CVD, n (%)      | 42 (6.5)       | 25 (3.8)       | 21 (3.2)       | 15 (2.3)       | 11 (1.7)       | 0.61*          |
| Obesity, n (%)  | 402 (61.8)     | 405 (62.2)     | 392 (60.1)     | 370 (56.8)     | 302 (46.4)     | <0.0001*       |

* Adjusted for age
Table 2. Partial correlation coefficient of LTL with obesity traits and related factors (N=3256)

| Variables                        | Correlation coefficient | P-value |
|----------------------------------|-------------------------|---------|
| Age                              | -0.35                   | <0.0001 |
| Education in years               | 0.01                    | 0.60    |
| Energy intake                    | -0.02                   | 0.21    |
| Waist circumference              | -0.13                   | <0.0001 |
| Percent body fat                 | -0.12                   | <0.0001 |
| Body mass index                  | -0.13                   | <0.0001 |
| Waist-to-hip ratio               | -0.11                   | <0.0001 |
| Waist-to-height ratio            | -0.15                   | <0.0001 |
| High-sensitivity C-reactive protein | -0.09                | <0.0001 |

*Adjusted for age and gender where appropriate

Table 3. Multivariate association of LTL with anthropometric measurements in American Indians *

| Variables                        | LTL | β (95% CI)        | P         | P for trend |
|----------------------------------|-----|------------------|-----------|-------------|
| Waist circumference              | Continuous | -5.96 (-8.70 - -3.22) | <.0001 |
| Q1 vs. Q5                        | 3.92 ( 2.05 - 5.79) | <.0001 |
| Q2 vs. Q5                        | 2.79 ( 0.93 - 4.65) | 0.003    |
| Q3 vs. Q5                        | 2.86 ( 0.88 - 4.85) | 0.005    |
| Q4 vs. Q5                        | 2.76 ( 0.78 - 4.75) | 0.007    |
| Percent body fat                 | Continuous | -1.50 (-2.74 - -0.26) | 0.02       |
| Q1 vs. Q5                        | 0.77 (-0.12 - 1.66) | 0.09     |
| Q2 vs. Q5                        | 0.84 ( 0.06 - 1.62) | 0.04     |
| Q3 vs. Q5                        | 0.75 (-0.15 - 1.64) | 0.10     |
| Q4 vs. Q5                        | 1.04 ( 0.08 - 1.99) | 0.03     |
| Body mass index                  | Continuous | -2.56 (-3.78 - -1.33) | <.0001       |
| Q1 vs. Q5                        | 1.49 ( 0.62 - 2.36) | 0.0009   |
| Q2 vs. Q5                        | 1.42 ( 0.58 - 2.26) | 0.001    |
| Q3 vs. Q5                        | 1.27 ( 0.43 - 2.11) | 0.003    |
| Q4 vs. Q5                        | 1.08 ( 0.16 - 2.01) | 0.02     |
| Waist-to-hip ratio               | Continuous | -0.023 (-0.032 - -0.014) | <.0001 |
| Q1 vs. Q5                        | 0.016 ( 0.008 - 0.023) | <.0001 |
| Q2 vs. Q5                        | 0.006 (-0.001 - 0.013) | 0.08     |
| Q3 vs. Q5                        | 0.010 ( 0.003 - 0.017) | 0.008    |
| Q4 vs. Q5                        | 0.009 ( 0.002 - 0.016) | 0.02     |
| Waist-to-height ratio            | Continuous | -0.038 (-0.054 - -0.022) | <.0001 |
| Q1 vs. Q5                        | 0.024 ( 0.013 - 0.036) | <.0001 |
| Q2 vs. Q5                        | 0.017 ( 0.007 - 0.028) | 0.002    |
| Q3 vs. Q5                        | 0.017 ( 0.006 - 0.029) | 0.004    |
| Q4 vs. Q5                        | 0.017 ( 0.005 - 0.028) | 0.007    |

*Adjusted for age, sex, study center, education, smoking, alcohol drinking, and total energy intake, hsCRP, hypertension and diabetes.
Clinical characteristics of study participants according to LTL quintiles are shown in Table 1. Compared to participants in the highest quintile of LTL (longest telomere length), those with shorter LTL had higher levels of WC, BMI, WHR, WHtR, and hsCRP after adjustment for age. Prevalence of obesity and diabetes were significantly higher among participants in the lowest LTL quintile than that in the highest quintile. Prevalence of obesity in participants with 1st through 5th quintile of LTL was 61.8%, 62.2%, 60.1%, 56.8% and 46.4% (age-adjusted P for trend <0.0001), respectively. The corresponding prevalence of diabetes was 31.5%, 27.3%, 19.5%, 14.9% and 9.7%, respectively (age-adjusted P for trend <0.0001).

Table 2 presents the partial correlation coefficients of LTL with obesity parameters and risk factors. LTL was negatively correlated with age (sex-adjusted $r = -0.35$, P<0.0001). After adjustments for both age and gender, LTL remained significantly and inversely correlated with all obesity indices and hsCRP (all P < 0.001).

| LTL       | OR  | 95% CI     | P value | P for trend |
|-----------|-----|------------|---------|-------------|
| **Model 1** |     |            |         |             |
| Continuous | 0.49 | 0.35 – 0.71 | 0.0001  |             |
| Q1 vs. Q5 | 1.58 | 1.23 - 2.02 | 0.0003  |             |
| Q2 vs. Q5 | 1.58 | 1.24 - 2.00 | 0.0002  |             |
| Q3 vs. Q5 | 1.54 | 1.23 - 1.92 | 0.0002  |             |
| Q4 vs. Q5 | 1.39 | 1.08 - 1.80 | 0.0108  | <0.001      |
| **Model 2** |     |            |         |             |
| Continuous | 0.49 | 0.35 – 0.70 | <0.0001 |             |
| Q1 vs. Q5 | 1.55 | 1.22 - 1.97 | 0.0003  |             |
| Q2 vs. Q5 | 1.53 | 1.18 - 1.98 | 0.0014  |             |
| Q3 vs. Q5 | 1.49 | 1.19 - 1.88 | 0.0006  |             |
| Q4 vs. Q5 | 1.36 | 1.04 - 1.78 | 0.0245  | 0.0002      |
| **Model 3** |     |            |         |             |
| Continuous | 0.56 | 0.40 – 0.79 | 0.001   |             |
| Q1 vs. Q5 | 1.39 | 1.10 - 1.76 | 0.0078  |             |
| Q2 vs. Q5 | 1.37 | 1.04 - 1.79 | 0.0275  |             |
| Q3 vs. Q5 | 1.40 | 1.11 - 1.78 | 0.0039  |             |
| Q4 vs. Q5 | 1.27 | 0.97 - 1.66 | 0.0794  | 0.0065      |

Model 1: adjusted for age, sex, and study center; Model 2: further adjusted for education, smoking, alcohol drinking, and total energy intake; Model 3: additionally adjusted for high-sensitivity C reactive protein, hypertension and diabetes.
Association of LTL with adiposity traits

LTL as a continuous variable was inversely associated with all obesity measurements after adjustments for age, sex, study center, education, lifestyle factors, hsCRP, hypertension and diabetes. On average, one unit decrease in LTL was associated with 5.96 cm increase in WC, 1.50% increase in %BF, 2.56 kg/m² increase in BMI, 0.02 unit increase in WHR and 0.04 unit increase in WHtR. Compared to participants whose LTL was in the highest quintile, those in the lowest quintile had significantly higher WC, BMI, WHR and WHtR (all P ≤ 0.001). Multivariable-adjusted association of LTL with adiposity phenotypes was shown in Table 3.

In the model treating obesity as a categorical variable (yes/no), participants with shorter LTL (lowest LTL quintile) were more likely to be obese than those with longer LTL (highest LTL quintile, OR=1.39; 95% CI, 1.10-1.76). Results are shown in Table 4. Additional adjustments for physical activity level or batch effect did not change the results. The observed associations also persisted after excluding children from statistical analysis.

DISCUSSION

In a large, well-characterized population of American Indians, LTL is inversely correlated with all obesity indices. Short LTL was significantly associated with obesity and related adiposity measurements, independent of traditional risk factors including chronological age, lifestyle factors, and obesity-related inflammation or comorbidities, e.g., diabetes and hypertension. Our findings may shed light on the potential mechanisms linking biological aging, obesity, and age-related disorders.

Several previous studies have examined the association of telomere length with obesity, but results were inconsistent, and the relationship between telomere shortening and obesity remains largely inconclusive. In a population of 1,122 white women, obese individuals had significantly shorter LTL than lean women [9]. A recent meta-analysis also revealed an inverse association between LTL and BMI in cross-sectional studies [25]. In a 5-year intervention trial, improvement in obesity indices in response to Mediterranean diet paralleled with increasing telomere length [10]. Further study indicated that the beneficial effects of Mediterranean diet on longevity could likely be determined by telomere maintenance [11]. Weight gain was also accompanied by reduced TL among obese women [8], but the favorable effect of weight loss and exercise on telomere length was unable to be replicated in postmenopausal women [16]. These discrepant results indicate that the relationship between telomere shortening, biological aging and obesity could be very complex.

Inflammation is an important biological mechanism known to be implicated in obesity [26], and telomere shortening has also been associated with inflammation [27]. In our analysis, LTL was negatively correlated with hsCRP, but the associations between telomeres and obesity indices were not substantially attenuated after further adjustment for hsCRP, suggesting that this association may not attribute to obesity-related inflammation. However, it should be noted that, hsCRP might not reflect the entire spectrum of inflammatory processes, although it is one of the most sensitive acute-phase reactant and has been widely used as an indicator of inflammation. In addition, different populations may have different inflammatory profiles, and thus future research should also investigate whether the observed association of telomeres with obesity in our study is independent of other inflammatory biomarkers in different populations. Moreover, the observed association of LTL with obesity withstood additional adjustments for diabetes or hypertension, indicating that this association may not be attributable to these two comorbidities.

Up to date, limited research has investigated the potential biological mechanisms underlying the linkage between accelerated telomere shortening and obesity. A previous study in mice demonstrated that telomere shortening may contribute to metabolic dysfunction through its impact on mitochondrial biogenesis [28]. In a recent experimental study, disruption of Rap1, a telomere-binding protein, resulted in a cascade of metabolic dysfunction, and Rap1-deficient mice exhibited accumulation of abdominal fat, insulin resistance, and other metabolic abnormalities, revealing a critical role of telomeres proteins in body weight homeostasis [29, 30]. The mammalian target of rapamycin (mTOR) pathway may represent another important biological mechanism linking telomeric aging to obesity, because mTOR pathway integrates insulin and nutrient signaling in numerous cell types and enhanced mTOR signaling has been implicated in cellular senescence. [31-33] Moreover, hyperactivity of the mTOR signaling has been associated with obesity and its related traits such as insulin resistance, type 2 diabetes, and cardiovascular diseases [34-37]. Furthermore, rapamycin slows down aging, prevents age-related diseases and extends maximal lifespan in mice.[37] These investigations open new avenues for understanding the potential significance of accelerated biological aging in obesity and other age-related disorders.
Numerous previous studies have reported that indicators of abdominal obesity (e.g., WC, WHtR) are better discriminators of cardiometabolic risk than indices of general obesity (e.g., BMI, %BF) [38-42]. Given that accelerated aging may represent a common denominator of obesity and related cardiometabolic comorbidities, it would be interesting to examine whether telomere length differentially influences body fat distribution, and if so, whether this explains the observed differential effect of body fat distribution on cardiometabolic risk. In this large, community-based epidemiological study of American Indians, LTL was inversely associated with all indices of obesity. We did not observe a differential effect of telomeric aging on body fat distribution, though the association of telomere length with abdominal obesity (e.g., WC) appears to be stronger than that with general obesity (e.g., BMI, %BF).

Several limitations of this study deserve mention. First, the cross-sectional nature of our analysis precludes any causal inference. Second, our results were derived from a cohort of American Indians who suffer from high rates of obesity and diabetes, and may also have distinct genetic and lifestyle risk profiles, so generalizability to other populations is unknown. However, given the rising tides of obesity and diabetes in other populations, it is plausible to speculate that our findings could be generalized to the general population. In addition, because many of the participants in our study population were centrally obese, the observed associations need to be confirmed in other cohorts. Finally, although we were able to control many of the known risk factors, we cannot entirely exclude the possibility of confounding by other unknown or unmeasured risk factors. Nonetheless, this is the first study to examine the association between LTL and obesity in a large, population-based study of American Indians. The comprehensive clinical phenotyping, the high quality telomere data, and a careful control for possible confounding factors represent the major strengths of the current investigation.

In summary, LTL was negatively associated with obesity in American Indians participating in the SHFS, independently of chronological age, lifestyle factors and obesity-related inflammation or comorbidities. Findings from this study provide valuable information towards a better understanding of obesity, and also highlight the importance of accelerated biological aging in obesity pathology.

METHODS

Study population. The Strong Heart Family Study (SHFS), a component of the Strong Heart Study (SHS), is a multicenter, family-based prospective study designed to identify genetic factors for CVD and their risk factors in American Indians. The study was initiated in 2001-2003 by recruiting 3,665 individuals (14-93 years old) from 13 tribes in Arizona (AZ), Oklahoma (OK) and North/South Dakota (DK). Study participants underwent a clinical examination including a personal interview and physical examination. Information on demographic factors, socioeconomic status, medical history, medication use, and lifestyle factors was collected by personal interview using standard questionnaires. A physical examination was conducted, and fasting blood samples were collected for laboratory tests, including fasting glucose, insulin, highsensitivity C-reactive protein (hsCRP), lipids and creatinine. Study design and methods of the SHFS have been reported previously [43, 44]. The SHFS protocol was approved by the Institutional Review Boards from the Indian Health Service and the participating study centers. All participants gave informed consent.

Among the 3,665 participants, 3,492 participants had completed data of telomere length and anthropometric measurements. Because some conditions may significantly influence body weight, we excluded individuals with cirrhosis of liver (n=50), chronic renal failure (n=55), cancer (n=141) or women who were pregnant at the time of clinical visit (n=5). The remaining 3,256 participants were included in the present investigation.

Assessments of obesity and related traits. Anthropometric measurements included body weight, height, waist circumference (WC) and hip circumference measured with participants wearing light clothing and without shoes by trained study researchers. Body height and weight were measured for each participant in a standing position. WC was measured at the level of the umbilicus while the participant was in a supine position. Hip circumference was measured at the level of widest circumference over greater trochanters with the legs close together in a standing position. BMI was defined as body weight in kilograms divided by the square of the height in meters (kg/m²). WHR was calculated as waist circumference divided by hip circumference. Waist-to-height ratio (WHtR) was calculated as waist circumference divided by height. Percent body fat (%BF) was estimated with an RJL impedance meter (Model B14101; RJL Equipment Company, Detroit, MI) using an equation based on total body water [45, 46]. In participants aged 18 years and older (n=2,927), obesity was defined as BMI ≥ 30 kg/m² according to the National Institutes of Health (NIH) guidelines [47]. Among children (<18 years old) (n=329), obesity was defined as BMI ≥ 95th percentile by age and gender.
Assessments of covariates. Education level was collected by standard questionnaires. Education level was coded into three categories (1 = less than high school, reference; 2 = high school graduate; 3 = some college or higher). Cigarette smokers were defined as persons who smoked at least 100 cigarettes during their lifetime. Those who were smoking cigarette at the visit time were classified as current smokers. Current drinkers are those who had consumed any alcohol during the past year. Dietary intake was assessed using the Willett self-administered semi-quantitative food frequency questionnaire (FFQ) [49], which collected dietary data for the 12 months prior to testing. Each participant received a pedometer, instructions for wearing the pedometer, and an activity diary at their clinical examination. They were asked to wear the pedometer for seven consecutive days and to record the number of the steps taken daily in the activity diary. Physical activity was assessed by the mean number of steps per day calculated by averaging the total number of steps recorded each day during the 7-day period. Hypertension was defined as blood pressure levels of 140/90 mm Hg or higher or current use of antihypertensive medications [50]. According to the American Diabetes Association criteria, diabetes was defined as fasting plasma glucose $\geq 7.0$ mmol/L or receiving insulin or oral hyperglycemic treatment [51].

Measurement of leukocyte telomere length (LTL). Genomic DNA from peripheral blood was isolated according to standard methods. LTL, as measured by T/S ratio, was performed by Dr. Elizabeth Blackburn’s laboratory at the University of California, San Francisco using an automated, high-throughput telomere length assay system. Detailed lab protocols and methods have been described previously. [3, 20] Briefly, LTL was quantified by qPCR using a serially diluted standard DNA and the standard curve method. The ratio of the telomeric product vs. the single copy gene reflects the average length of the telomeres. A single copy gene was amplified in parallel to normalize the quantity of the input DNA. Each DNA sample was assayed three times and the mean value was used in statistical analysis. For quality control, we included seven control DNA samples from various cancer cell lines in each assay plate. These control samples allowed us to create standard curves, which were then integrated into a composite standard curve used for T and S concentration calculations. The intra- and inter-assay %CV was 4.6% and 6.9%, respectively. Lab technicians were blinded to any knowledge of clinical data.

Statistical analyses. Clinical characteristics of the study participants were compared across the quintiles of LTL. Cross-sectional association of LTL with each obesity phenotype (dependent variable) was assessed using linear mixed model, including WC, %BF, BMI, WHR, and WHtR, adjusting for established risk factors for obesity (described below). Linear mixed model was used here to account for the lack of independence among family members. In the association analyses, LTL was first analyzed as a continuous variable, and then categorized into quintiles to facilitate interpretation. Regression coefficient and 95% confidence interval (CI) for each measurement was assessed by constructing a series of hierarchical models adjusting for potential confounders: Model 1, adjusted for age, sex, and study center; Model 2, further adjusted for education and lifestyle factors including smoking, alcohol drinking, and total energy intake; Model 3, additionally adjusted for hsCRP, hypertension and diabetes. The odds ratio (OR) and 95% CI for the association of LTL with obesity (yes/no) were assessed using multivariate logistic regression model implemented in GLIMMIX procedure in SAS. All statistical analyses were done using SAS 9.3 (SAS Institute, Inc., Cary, NC).

Given the close relationship of physical activity with obesity, we additionally adjusted for level of physical activity to examine whether it influences the association between LTL and obesity. To examine whether inclusion of children influences the association of LTL with obesity, we conducted additional analysis by excluding children (aged <18 years, n=329) from statistical analysis. To examine whether and how batch effects influence our results, we conducted additional analysis by further adjusting for batch in the above statistical model.

ACKNOWLEDGEMENTS

The authors would like to thank the Strong Heart Study (SHS) participants, Indian Health Service facilities, and participating tribal communities for their extraordinary cooperation and involvement, which has contributed to the success of the SHS. The views expressed in this article are those of the authors and do not necessarily reflect those of the Indian Health Service.

Sources of Funding

This study was supported by National Institutes of Health grants R01DK091369, K01AG034259, R21HL092363 and cooperative agreement grants U01HL65520, U01HL41642, U01HL41652, U01HL41654, and U01HL65521. Dr. Chen was supported by a research.
training grant (D43TW009107) from NIH John E Fogarty International Center, Bethesda, MD.

**Conflict of interest statement**

Authors declare no conflict of interests.

**REFERENCES**

1. Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet. 2009; 10:45-61.
2. Lung FW, Ku CS and Kao WT. Telomere length may be associated with hypertension. J Hum Hypertens. 2008; 22:230-232.
3. Zhao J, Zhu Y, Lin J, Matsuuguichi T, Blackburn E, Zhang Y, Cole SA, Best LG, Lee ET and Howard BV. Short leukocyte telomere length predicts risk of diabetes in american indians: the strong heart family study. Diabetes. 2014; 63:354-362.
4. Brouillet S, Singh RK, Thompson JR, Goodall AH and Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003; 23:842-846.
5. Brouillet SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ and Samani NJ. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007; 369:107-114.
6. Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, Dunning AM, Svensson U, Roos G, Hosgood HD, 3rd, Shen M and Wei Q. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One. 2011; 6:e20466.
7. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, Kronenberg F and Kiechl S. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010; 304:69-75.
8. Kim S, Parks CG, DeRoo LA, Chen H, Taylor JA, Cawthon RM and Sandler DP. Obesity and weight gain in adulthood and telomere length. Cancer Epidemiol Biomarkers Prev. 2009; 18:816-820.
9. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelesn E, Cherkas LF, Aviv A and Spector TD. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005; 366:662-664.
10. Garcia-Calzon S, Gea A, Razquin C, Corella D, Lamuela-Raventos RM, Martinez JA, Martinez-Gonzalez MA, Zalba G and Marti A. Longitudinal association of telomere length and obesity indices in an intervention study with a Mediterranean diet: the PREDIMED-NAVARRA trial. Int J Obes (Lond). 2014; 38:177-182.
11. Boccardi V, Esposito A, Rizzo MR, Marfella R, Barbieri M and Paolisso G. Mediterranean diet, telomere maintenance and health status among elderly. PLoS One. 2013; 8:e62781.
12. O'Callaghan NJ, Clifton PM, Noakes M and Fenech M. Weight loss in obese men is associated with increased telomere length and decreased abasic sites in rectal mucosa. Rejuvenation Res. 2009; 12:169-176.
13. Al-Attas OS, Al-Daghri N, Bamakshrah A, Shaua Sabico S, McTernan P and Huang TT. Telomere length in relation to insulin resistance, inflammation and obesity among Arab youth. Acta Paediatr. 2010; 99:896-899.
14. Bekart S, De Meyer T, Rietzschel ER, De Buyzere ML, De Bacquer D, Langlois M, Segers P, Cooman L, Van Damme P, Cassiman P, Van Criekinge W, Verdonck P, De Backer GG, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell. 2007; 6:639-647.
15. Bischoff C, Petersen HC, Graakjaer J, Andersen-Ranberg K, Vaupel JW, Bohr VA, Kolvraa S and Christensen K. No association between telomere length and survival among the elderly and oldest old. Epidemiology. 2006; 17:190-194.
16. Mason C, Riques RA, Xiao L, Duggan CR, Imayama I, Campbell KL, Kong A, Foster-Schubert KE, Wang CY, Alfano CM, Blackburn GL, Rabinovich PS and McTiernan A. Independent and combined effects of dietary weight loss and exercise on leukocyte telomere length in postmenopausal women. Obesity (Silver Spring). 2013; 21:E549-554.
17. Njouj OT, Cawthon RM, Blackburn EH, Harris TB, Li R, Sanders JL, Newman AB, Nalls M, Cummings SR and Hsu WC. Shorter telomeres are associated with obesity and weight gain in the elderly. Int J Obes (Lond). 2012; 36:1176-1179.
18. Broer L, Codj V, Nyholt DR, Deelen J, Mangino M, Willemsen G, Albrecht E, Amin N, Beekman M, de Geus EJ, Henders A, Nelson CP, Steves CJ, et al. Meta-analysis of telomere length in 19,713 subjects reveals high heritability, stronger maternal inheritance and a paternal age effect. Eur J Hum Genet. 2013; 21:1163-1168.
19. Llewellyn CH, Trzaskowski M, Plomin R and Wardle J. Finding the missing heritability in pediatric obesity: the contribution of genome-wide complex trait analysis. Int J Obes (Lond). 2013; 37:1506-1509.
20. Zhu Y, Voruganti VS, Lin J, Matsuuguichi T, Blackburn E, Best LG, Lee ET, MacCluer JW, Cole SA and Zhao J. QTL mapping of leukocyte telomere length in American Indians: the Strong Heart Family Study. Aging (Albany NY). 2013; 5:704-716.
21. Huzen J, Wong LS, van Veldhuisen DJ, Samani NJ, Zwierderman AH, Codj V, Cawthon RM, Benus GF, van der Horst IC, Navis G, Bakker SJ, Gansevoort RT, de Jong PE, et al. Telomere length loss due to smoking and metabolic traits. J Intern Med. 2014; 275:155-163.
22. Ravussin E, Valencia ME, Esparza J, Bennett PH and Schulz LO. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes Care. 1994; 17:1067-1074.
23. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013; 127:e6-e245.
24. Broussard BA, Sugarman JR, Bachman-Carter K, Booth K, Stephenson L, Strauss K and Gohdes D. Toward comprehensive obesity prevention programs in Native American communities. Obes Res. 1995; 3 Suppl 2:289s-297s.
25. Muezzinler A, Zaineddin AK and Brenner H. Body mass index and leukocyte telomere length in adults: a systematic review and meta-analysis. Obes Rev. 2014; 15:192-201.
26. Shoelson SE, Herrero L and Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007; 132:2169-2180.
27. O’Donovan A, Pantell MS, Puterman E, Dhabhar FS, Blackburn EH, Yaffe K, Cawthon RM, Oppreko PL, Hsuwe WC, Satterfield S, Newman AB, Ayonoyon HN, Rubin SM, et al. Cumulative inflammatory load is associated with short leukocyte telomere length in the Health, Aging and Body Composition Study. PLoS One. 2011; 6:e19687.
28. Sahin E, Colla S, Liesz M, Moslehi J, Muller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster
F, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature. 2011; 470:359-365.
29. Martinez P, Gomez-Lopez G, Garcia F, Mercken E, Mitchell S, Flores JM, de Cabo R and Blasco MA. Rap1 protects from obesity through its extratelomeric role regulating gene expression. Cell Rep. 2013; 3:2059-2074.
30. Yeung F, Ramirez CM, Mateos-Gomez PA, Pinzaru A, Ceccarini G, Kabir S, Fernandez-Hernando C and Sfeir A. Nontelomeric role for Rap1 in regulating metabolism and protecting against obesity. Cell Rep. 2013; 3:1847-1856.
31. Pospelova TV, Bykova TV, Zubova SG, Katolikova NV, Yartzeva NM and Pospelov VA. Rapamycin induces pluripotent genes associated with avoidance of replicative senescence. Cell cycle. 2013; 12:3841-3851.
32. Kolesnichenko M, Hong L, Liao R, Vogt PK and Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell cycle. 2012; 11:2391-2401.
33. Leontieva OV, Lenzo F, Demidenko ZN and Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell cycle. 2012; 11:4642-4649.
34. Laplante M and Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149:274-293.
35. Yang Z and Ming XF. mTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases. Obes Rev. 2012; 13 Suppl 2:58-68.
36. Kuhlow D, Florian S, von Figura G, Weimer S, Schulz N, Petzke KJ, Zarse K, Pfeiffer AF, Rudolph KL and Ristow M. Telomerase deficiency impairs glucose metabolism and insulin secretion. Aging (Albany NY). 2010; 2:650-658.
37. Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell death & disease. 2013; 4:e964.
38. Czernichow S, Kengne AP, Stamatakis E, Hamer M and Batty GD. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk? Evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev. 2011; 12:680-687.
39. Lee CM, Huxley RR, Wildman RP and Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008; 61:646-653.
40. Recio-Rodriguez JJ, Gomez-Marcos MA, Patino-Alonso MC, Agudo-Conde C, Rodriguez-Sanchez E and Garcia-Ortiz L. Abdominal obesity vs general obesity for identifying arterial stiffness, subclinical atherosclerosis and wave reflection in healthy, diabetics and hypertensive. BMC Cardiovasc Disord. 2012; 12:3.
41. Savva SC, Lamnisos D and Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI: a meta-analysis. Diabetes Metab Syndr Obes. 2013; 6:403-419.
42. Schneider HJ, Friedrich N, Klotzsche J, Pieper L, Nauck M, John U, Dorr M, Felix S, Lehnert H, Pittrow D, Silber S, Volzke H, Stalla GK, et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab. 2010; 95:1777-1785.
43. Lee ET, Welty TK, Fabszitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, Savage PJ and Howard BV. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990; 132:1141-1155.
44. North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabszitz RR, Roman MJ and MacCluer JW. Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol. 2003; 157:303-314.
45. Hoffer EC, Meador CK and Simpson DC. Correlation of whole-body impedance with total body water volume. J Appl Physiol. 1969; 27:531-534.
46. Lukaski HC, Johnson PE, Bolonchuk WW and Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985; 41:810-817.
47. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary. Am J Clin Nutr. 1998; 68:899-917.
48. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawin LM, Curtin LR, Roche AF and Johnson CL. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002; 109:45-60.
49. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH and Speizer FE. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985; 122:51-65.
50. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT and Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206-1252.
51. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20:1183-1197.
**SUPPLEMENTARY TABLE**

**Table S1. Comparison of clinical characteristics between obese and non-obese participants**

| Variables                      | Non-obesity | Obesity | P-value |
|--------------------------------|-------------|---------|---------|
| N                              | 1385        | 1871    |         |
| LTL                            | 1.02±0.25   | 0.97±0.22 | 0.0003  |
| Age (yrs)                      | 37.9±17.8   | 39.4±15.5 | 0.58    |
| Men, n (%)                     | 621(44.8)   | 694(37.1) | 0.001   |
| Education (yrs)                | 11.8±2.3    | 11.9±2.3 | 0.04    |
| Total energy intake (kcal)     | 2762±2206   | 2658±1956 | 0.61    |
| Waist circumference (cm)       | 89.0±10.3   | 115.3±14.6 | <0.0001 |
| Hip circumference (cm)         | 101.9±7.4   | 123.4±13.5 | <0.0001 |
| Percent body fat (%)           | 30.1±8.2    | 42.5±8.2 | <0.0001 |
| BMI (kg/m²)                    | 25.4±3.2    | 37.22±6.3 | <0.0001 |
| WHR                            | 0.87±0.07   | 0.94±0.07 | <0.0001 |
| WHtR                           | 0.53±0.06   | 0.69±0.09 | <0.0001 |
| Systolic blood pressure (mmHg) | 119.7±17.3  | 123.7±15.8 | <0.0001 |
| Diastolic blood pressure (mmHg)| 74.3±11.1   | 77.8±11.0 | <0.0001 |
| Fasting glucose (mg/dL)        | 103.8±45.5  | 120.5±56.0 | <0.0001 |
| Total cholesterol (mg/dL)      | 178.8±37.4  | 182.2±34.2 | 0.31    |
| Triglyceride (mg/dL)           | 142.8±137.7 | 181.3±131.2 | <0.0001 |
| LDL-c (mg/dL)                  | 96.8±30.0   | 99.8±28.3 | 0.04    |
| HDL-c (mg/dL)                  | 54.6±15.5   | 47.9±13.0 | <0.0001 |
| hsCRP (mg/L)                   | 4.6±9.3     | 8.2±8.6  | <0.0001 |
| Physical activity (steps/day)  | 6696±4193   | 5082±3490 | <0.0001 |
| Current smoking, n (%)         | 537 (38.9)  | 577 (30.9) | <0.0001 |
| Current drinking, n (%)        | 855 (61.9)  | 1070 (57.3) | 0.003  |
| Hypertension, n (%)            | 323 (23.4)  | 695 (37.2) | <0.0001 |
| Diabetes, n (%)                | 165 (11.9)  | 504 (27.0) | <0.0001 |
| CVD, n (%)                     | 39 (2.8)    | 75 (4.0)  | 0.03    |